Introduction

No single weight-loss medicine suits everyone. GLP-1 injections, fat-blocking tablets, central appetite regulators and dual-hormone therapies all work differently and come with their own pros and cons. Choosing the right option depends on your medical history, BMI, lifestyle preferences and goals. This guide compares four approaches used in UK private care:

GLP-1 analogues (e.g. semaglutide, liraglutide).
Orlistat, a fat-absorption blocker.
Orforglipron, an emerging oral GLP-1 receptor agonist.
Dual-incretins (tirzepatide), which stimulate both GLP-1 and GIP pathways.

If you want to understand why dual-hormone medicines are becoming the next major step in obesity + diabetes care, read our guide on the future of dual-action medications and how they target blood sugar and appetite together.

Always discuss weight-loss medicines with a UK-registered prescriber. They will evaluate your health, BMI, and weight-related risks to decide which treatment -if any -is appropriate.

For a deeper look at how Orforglipron compares directly with tirzepatide in terms of mechanism, effectiveness, and convenience, check out our full comparison in Orforglipron vs Tirzepatide: How Will the New Weight Loss Pill Compare?

How They Work

GLP-1 Analogues (Injectable)

These drugs mimic the gut hormone GLP-1, which increases feelings of fullness, slows stomach emptying and stabilises blood sugar. Weekly or daily injections help reduce appetite and cravings by enhancing natural satiety signals.

For a deeper dive on appetite effects, see GLP-1 medicines and appetite fullness (UK guide).

Helpful resources while on treatment:

Orlistat (Fat-Blocking Tablet)

Orlistat is a lipase inhibitor. It prevents about one-third of the fat you eat from being absorbed. The undigested fat passes through the gut, so you need to follow a low-fat diet to minimise unpleasant side effects.

Orforglipron (Oral GLP-1 Tablet)

Orforglipron Tablet is a new small-molecule GLP-1 receptor agonist. It mimics GLP-1, reducing hunger and slowing digestion. Early trials show promising weight-loss results; it remains in phase 3 trials. Being a tablet, it could offer the benefits of GLP-1 injections without the need for needles.

Dual-Incretins (Tirzepatide)

Tirzepatide stimulates both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. This dual action leads to greater increases in incretin hormones, promoting insulin release, reducing liver glucose production and further slowing digestion. It’s currently available via private care and is being rolled out through the NHS for people with high BMI and weight-related conditions.

Comparison Grid

GLP-1 Analogue

How It Works: Mimics GLP-1 to enhance satiety and slow gastric emptying.

Route & Frequency: Weekly (semaglutide) or daily (liraglutide) injection.

Typical Tolerability: Early GI effects (nausea, indigestion, constipation) common -see GLP-1 side effects.

Monitoring Needs: Clinical review for dose titration and side-effect support -see dose titration in the first 12 weeks.

Suitability Highlights: Suitable for those needing appetite support plus cardiometabolic review; check GLP-1 therapy eligibility (UK).

Orlistat

How It Works: Blocks gut enzymes to prevent ~⅓ of dietary fat absorption.

Route & Frequency: Capsule taken with each fatty meal.

Typical Tolerability: Oily stools, urgent bowel movements and flatulence if diet is high in fat.

Monitoring Needs: Dietary counselling; monitor fat intake.

Suitability Highlights: Ideal for patients who prefer tablets and can follow a low-fat diet.

Orforglipron Tablet

How It Works: Mimics GLP-1; reduces hunger, slows digestion, lowers blood sugar.

Route & Frequency: Once-daily tablet.

Typical Tolerability: Mostly mild GI side effects (nausea, vomiting, diarrhoea, constipation).

Monitoring Needs: Still in phase 3 trials; not yet licensed; long-term safety under review.

Suitability Highlights: Emerging option for those who need GLP-1 benefits but prefer tablets; discuss availability.

Dual-Incretin (Tirzepatide)

How It Works: Activates both GLP-1 and GIP receptors to increase incretin hormones, boost insulin and slow digestion.

Route & Frequency: Weekly injection, titrated from 2.5 mg to 15 mg.

Typical Tolerability: Similar GI profile to GLP-1 analogues; risk of hypoglycaemia with insulin.

Monitoring Needs: Regular clinical review; caution in pregnancy; use only if prescriber-approved.

Suitability Highlights: Emerging NHS/private option for those needing greater weight-loss efficacy.

Choosing with a Clinician

Your prescriber will consider:

Medical history: Underlying conditions (e.g. pancreatitis, gallbladder disease, mental health) can determine which drugs are safe or unsuitable.
Treatment goals: Do you need significant weight loss, blood-sugar control, or appetite suppression?
Preference for injections or tablets: Some people prefer weekly injections; others want to avoid needles.
Cost & availability: Orlistat is widely available and low cost; tirzepatide and orforglipron may have limited availability and higher cost.
Response to previous medications: If weight plateaus on one medicine or side effects are intolerable, your clinician may recommend switching or stepping up to a different class.

For suitability basics and prescriber criteria, see GLP-1 therapy eligibility in the UK and safety points in GLP-1 interactions & contraindications.

When to Switch or Step-Up

Switching or stepping up may be considered if:

Weight plateau: After several months on the highest tolerated dose with little additional weight loss.
Side-effect burden: Severe or persistent side effects despite dose adjustments — practical tips: managing GLP-1 side effects
Access issues: Medication shortages or cost constraints.
Development of new health conditions: For instance, if you develop high blood pressure, a prescriber might avoid Mysimba due to its potential to increase blood pressure.

Always consult your prescriber before making changes. Never combine weight-loss drugs unless directed by a clinician.

FAQs

Pills vs Injections -Which Is Better?

Tablets (Orlistat, Orforglipron) avoid needles but may cause specific side effects. Injectables (GLP-1, tirzepatide) are often more potent but involve weekly or daily injections and sharps disposal.

If you’re on GLP-1 therapy, consider GLP-1 meal ideas (UK) to support tolerance and satiety.

Can Options Be Combined?

Generally, no. Combining medicines like GLP-1 injections with Mysimba or Orlistat is not usually advised unless under specialist guidance. Combining treatments can increase side effects or risk of low blood sugar. Review safety basics here: GLP-1 interactions & contraindications (UK).

Why Isn’t Orforglipron Widely Available?

Orforglipron tablets are still in phase 3 trials and not yet licensed for use in the UK but will be available from Medcare Health Clinic & Pharmacy. Early results show promising weight loss — participants lost 8.6–12.6% of body weight by week 26, rising to 9.4–14.7% by week 36. Full approval depends on safety and efficacy data.

MedCare Health Clinic & Pharmacy

Personalised online consultations with UK-registered prescribers.

Access to licensed treatments including GLP-1 injections, Orlistat, and tirzepatide and soon Orforglipron.

Monitoring & aftercare: Our pharmacists guide you through dose titration, side-effect management and lifestyle support -see meal planning ideas for tolerance: GLP-1 meal ideas

Next-day delivery across England; discreet packaging and local collection available.

Disclaimer

This guide is for UK residents only and is not a substitute for professional medical advice. Always consult your GP, NHS 111 or a qualified prescriber. Weight-loss medicines are prescription-only and may carry risks; suitability and dosing must be assessed individually by a licensed prescriber.